Benitec recapitalising after US patent resolution opens up new opportunities
This article was originally published in Scrip
The Australian gene silencing firm Benitec is planning to raise around Aus$8 million ($8.4 million) in a renounceable rights issue, and plans to use the funds mainly to progress three preclinical therapeutic programmes.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.